Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial

Journal:
Nature Medicine
Published:
Affiliations:
23
Authors:
23
Institutions Authors Share
Johnson & Johnson, United States of America (USA)
8.000000
0.35
UCL, United Kingdom (UK)
1.000000
0.04
Huntsman Cancer Institute at the University of Utah (HCI), Utah, United States of America (USA)
1.000000
0.04
Peter MacCallum Cancer Centre (Peter Mac), Australia
1.000000
0.04
Houston Methodist Neal Cancer Center, United States of America (USA)
1.000000
0.04
Istanbul University Cerrahpaşa (IUC), Turkey
1.000000
0.04
Liga Norte Riograndense Contra o Câncer, Brazil
1.000000
0.04
Centro Integrado de Oncologia de Curitiba (CIONC), Brazil
1.000000
0.04
Hospital and Cancer Center, CQU, China
1.000000
0.04
Johnson & Johnson, Netherlands, Netherlands
1.000000
0.04
Instituto de Investigación Hospital 12 de Octubre (i+12), Spain
1.000000
0.04
Oregon Health and Science University (OHSU), United States of America (USA)
0.500000
0.02
VA Portland Health Care System (VAPORHCS), United States of America (USA)
0.500000
0.02
University of Calgary (U of C), Canada
0.500000
0.02
Southern Alberta Institute of Urology (SAIU), Canada
0.500000
0.02
University of Washington (UW), United States of America (USA)
0.500000
0.02
Fred Hutchinson Cancer Center, United States of America (USA)
0.500000
0.02
The University of British Columbia (UBC), Canada
0.500000
0.02
BC Cancer Agency (BCCA), PHSA, Canada
0.500000
0.02
Weill Cornell Medicine, United States of America (USA)
0.500000
0.02
Memorial Sloan Kettering Cancer Center (MSKCC), United States of America (USA)
0.500000
0.02